Astellas Pharma Inc., a Japan-based biopharmaceutical company, continues to make considerable strides in the biotech market. Key developments include a capsid license agreement with
Sangamo Therapeutics, aimed at delivering genomic medicines for neurological diseases, and an exclusive option and license agreement with
AviadoBio targeting Frontotemporal Dementia. The company faced a setback with one of its employees indicted in China, and layoffs at Ring and Astellas Gene Therapies. It opened new Life Sciences Centers in Cambridge and Massachusetts, promising breakthrough therapies and future innovations. Strategic collaborations with various organizations like
UMass Chan Medical School,
YASKAWA and
Mass General Brigham demonstrated its dedication to advancing scientific research and patient-centric care.
Astellas received significant regulatory approvals, notably FDA approval for its gastric cancer therapy, VYLOY™, and received a positive CHMP opinion for PADCEV™. Furthermore, Astellas has committed to utilizing AI for healthcare initiative, realized with FDA listing of DIGITIVA™ for heart failure management. Additionally, its partnership with
Takeda and
Sumitomo Mitsui Banking for incubating early drug discovery program, and its venture into allogeneic cell therapies in oncology with Poseida Therapeutics, mark exciting developments.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Thu, 19 Dec 2024 17:00:00 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 5
